RecruitingPhase 3NCT02633514
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma
Sponsor
Fudan University
Enrollment
1 participants
Start Date
Dec 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- \~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.
Exclusion Criteria1
- Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.
Interventions
DRUGCisplatin
25mg/m2,iv gtt,d1-3
DRUGEtoposide
75mg/m2,iv gtt,d1-3
RADIATIONradiotherapy
60Gy/30Fx
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02633514
Related Trials
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
NCT0679070615 locations
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
NCT066920621 location
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
NCT063019451 location